Keywords: medimmune, expects, leap, 1st-qtr, eps, cancer, infectious
MedImmune expects 170% leap in 1st-qtr EPS
Article | 16 April 2007
US cancer and infectious and inflammatory diseases specialist MedImmune has said that it anticipates its first-quarter 2007 diluted earnings per share, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
